The enduring success of copyright’s flagship drug has undeniably shaped the drug landscape. However, investing in companies heavily focused on generic versions and the declining patent exclusivity https://baidubookmark.com/story21222432/the-blue-pill-and-drugmakers-a-risky-opportunity